News for AYTU Stock

Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM) Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM) Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025 Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025 Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025 Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 Aytu BioPharma Disclosure Notification Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM) Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024 Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024 Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024 Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024 Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024 Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024 Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023 Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023 Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023 Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023 Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023 Aytu BioPharma to Present at LD Micro Main Event XVI Conference Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement Aytu to Participate in the Maxim Group Virtual Healthcare Conference Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023 Aytu BioPharma Subleases a Portion of Its Manufacturing Facility Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer Aytu BioPharma Reports Second Quarter of Fiscal Year 2023 Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023 Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023 Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31 Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients Aytu BioPharma Announces 1-for-20 Reverse Stock Split Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023 Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022 Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company's Term Loan Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT(R) in Response to Reported Generic Adderall(R) XR Supply Disruptions Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022 Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin Aytu BioPharma to Participate in September 2022 Investor Conferences Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R) Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit Aytu BioPharma to Participate in the 34th Annual Roth Conference Aytu BioPharma Announces Closing of $7.6 Million Registered Offering Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results Aytu BioPharma Completes $15 Million Debt Refinancing Aytu BioPharma Appoints Mark Oki as Chief Financial Officer Aytu BioPharma to Present at H.C. Wainwright BioConnect Conference Denovo Biopharma LLC Announces Partner Aytu BioPharma Receives FDA Clearance and Orphan Drug Designation for Enzastaurin in Vascular Ehlers-Danlos Syndrome Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome Aytu BioPharma Announces Issuance of First U.S. Patent Supporting Healight Ultraviolet-A Respiratory Catheter Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 50(TM) Aytu BioPharma Reports First Quarter 2022 Financial Results Aytu BioPharma to Report First Quarter Fiscal 2022 Results and Provide Business Update on November 15, 2021 CORRECTION: Aytu BioPharma to Present at Upcoming September Investor Conferences Aytu BioPharma Reports Fourth Quarter and Full-Year Fiscal 2021 Financial Results Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27, 2021 Aytu BioPharma Announces Formation of New Scientific Advisory Board to Support Development of AR101 for Vascular Ehlers-Danlos Syndrome Aytu BioPharma to Present at Upcoming September Investor Conferences Aytu BioPharma Announces Publication of Data Demonstrating Ultraviolet-A Light Reduces Cellular Cytokine Release from Human Endotracheal Cells Infected with Coronavirus Aytu BioPharma Announces Peer-Reviewed Publication of Clinical Results from Healight(TM) Pilot Study Aytu BioPharma to Present at Upcoming June Investor Conferences Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights Aytu BioPharma Announces Publication of In Vitro Study Demonstrating That Ultraviolet-A Light Increases Mitochondrial Anti-Viral Signaling Protein Within Cells Aytu BioPharma to Report Third Quarter Fiscal 2021 Results on May 17, 2021 Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics Aytu BioPharma Strengthens Leadership Team with Appointment of Richard Eisenstadt as Chief Financial Officer Aytu BioPharma Divests U.S. Rights to Natesto(R) to Acerus Pharma Aytu BioScience Announces Manufacture and Delivery of Healight(TM) Devices for Use in COVID-19 Clinical Study Aytu BioScience Announces Close of Merger with Neos Therapeutics Aytu BioScience Announces Positive Clinical Results from Healight(TM) Pilot Study in SARS-CoV-2 Patients Aytu BioScience to Present at Upcoming March Investor Conferences Aytu BioScience Announces Record Fiscal Q2 2021 Net Revenue of $15.1 Million, an Increase of 377% Year-Over-Year Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021 Aytu BioScience to Report Second Fiscal 2021 Results and Provide Business Update on Thursday, February 11, 2021 Aytu BioScience Announces Completion of Healight(TM) Safety Study in Critically Ill COVID-19 Patients Aytu BioScience to Present at the LD Micro Virtual Investor Conference on Tuesday, December 15 at 2:20pm ET Aytu BioScience Announces $10.0 Million Bought Deal Offering Aytu BioScience to Present at the Jefferies 2020 Virtual London Healthcare Conference Wednesday, November 18 at 1:45pm ET Aytu BioScience to Report First Quarter Fiscal 2021 Results and Provide Business Update on Thursday, November 12, 2020 Aytu BioScience Announces Fiscal Q4 2020 Net Revenue of $14.9 Million, an Increase of 82% Sequentially, and 766% Year-Over-Year Aytu BioScience to Report Fourth Quarter and Full Year Fiscal 2020 Results and Provide Business Update on Tuesday, October 6, 2020 Aytu BioScience to Reschedule Fourth Quarter and FY 2020 Conference Call Aytu BioScience to Report Fourth Quarter FY 2020 Results and Business Update on Thursday, September 24, 2020 Aytu BioScience Announces Global Agreement to Distribute Pinnacle IVD Corporation's 15-Minute COVID-19 Antigen Test Aytu BioScience Announces Launch of Nationwide Mobile COVID-19 Testing Initiative Aytu BioScience Announces Manufacture and Delivery of Healight(TM) Devices for Use in COVID-19 Clinical Study